One year of Nature Cancer

As we celebrate our first anniversary, we present a selection of articles we have published so far, highlighting key areas of our diverse scope. Visit the Collection site here!

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR Open Access.

Our Open Access option complies with funder and institutional requirements.


  • The election of Joe Biden to the US presidency has rekindled optimism in the world of science. To truly bring science to center stage will require bold political moves, the pulling together of all stakeholders, and time.

  • The complexity of glioblastoma is becoming increasingly recognized. Three recent studies used single-cell approaches that integrate cellular states, transcriptional trajectories, and metabolic alterations to uncover multiple dimensions of cellular and molecular heterogeneity and provide a framework for additional functional investigation and therapeutic development.

    • Christopher G. Hubert
    • Justin D. Lathia
    News & Views
  • Metabolic reprogramming mediates resistance to therapy and rewires cancer-cell-signaling networks, paving the way to the discovery of enhanced treatment strategies through acquired vulnerabilities. A study now points to lipotoxicity dependent on Raf-1 kinase that occurs after activation of the liver receptor LXRα as a therapeutic intervention for the treatment of hepatocellular carcinoma.

    • Suchira Gallage
    • Jose Efren Barragan Avila
    • Mathias Heikenwalder
    News & Views
  • The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, poses a clear and present danger to the health and well-being of populations. Here we discuss its indirect impact on global cancer prevention and control efforts, particularly for cervical cancer. We suggest some comparisons between the COVID-19 pandemic and the human papillomavirus–induced cancer burden, as well as opportunities for translating pandemic-control strategies into effective cancer control.

    • Ophira Ginsburg
    • Partha Basu
    • Karen Canfell
  • This month marks one year since the launch of Nature Cancer. As we celebrate our first anniversary, we reflect on the past year and thank the cancer research community for embracing our journal.

  • Inhibition of the anti-apoptotic protein BCL-2 has emerged as a highly effective treatment for acute myeloid leukemia; approved lower-intensity venetoclax combination therapies are now being rapidly incorporated into an improved standard of care for this cancer. Here we recount an abbreviated history of venetoclax for acute myeloid leukemia, focusing on a selection of key studies along the path from development into the clinic.

    • Courtney D. DiNardo
    • Marina Y. Konopleva
    Clinical Outlook
Clinical Cancer Genomics

Clinical Cancer Genomics

Advances in sequencing and genomic technologies are rapidly expanding our understanding of cancer and in turn the role of genomics in clinical oncology.